Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

620 ARTÍCULOS , VIENDO DEL 601 AL 615

Therapeutic potential of catalpol and geniposide in Alzheimer's and Parkinson's diseases: A snapshot of their underlying mechanisms

Zhang X, Liu K, Shi M, Xie L, Deng M, Chen H, Li X.

Brain Res Bull. 2021 Sep;174:281-295. doi: 10.1016/j.brainresbull.2021.06.020. Epub 2021 Jul 1.

Phosphodiesterase 7(PDE7): A unique drug target for central nervous system diseases

Chen Y, Wang H, Wang WZ, Wang D, Skaggs K, Zhang HT.

Neuropharmacology. 2021 Sep 15;196:108694. doi: 10.1016/j.neuropharm.2021.108694. Epub 2021 Jul 7.

Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer's and Parkinson's Diseases

Jagaran K, Singh M.

Int J Mol Sci. 2021 Aug 23;22(16):9082. doi: 10.3390/ijms22169082.

Exosomes in Alzheimer's Disease: From Being Pathological Players to Potential Diagnostics and Therapeutics

Soliman HM, Ghonaim GA, Gharib SM, Chopra H, Farag AK, Hassanin MH, Nagah A, Emad-Eldin M, Hashem NE, Yahya G, Emam SE, Hassan AEA, Attia MS.

Int J Mol Sci. 2021 Oct 6;22(19):10794. doi: 10.3390/ijms221910794.

Advances in Parkinson's Disease Drugs

Di Stefano A, Marinelli L.

Biomolecules. 2021 Nov 5;11(11):1640. doi: 10.3390/biom11111640.

Valproate-induced Periorbital Edema

Hatahet S, Khalaf K, Elhamamsy S.

R I Med J (2013). 2021 Dec 1;104(10):10-11.

Melatonin hormone as a therapeutic weapon against neurodegenerative diseases

Asefy Z, Khusro A, Mammadova S, Hoseinnejhad S, Eftekhari A, Alghamdi S, Dablool AS, Almehmadi M, Kazemi E, Sahibzada MUK.

Cell Mol Biol (Noisy-le-grand). 2021 Nov 25;67(3):99-106. doi: 10.14715/cmb/2021.67.3.13.

Recent Advances in the Potential of Cannabinoids for Neuroprotection in Alzheimer's, Parkinson's, and Huntington's Diseases

Pérez-Olives C, Rivas-Santisteban R, Lillo J, Navarro G, Franco R.

Adv Exp Med Biol. 2021;1264:81-92. doi: 10.1007/978-3-030-57369-0_6.

Microglia-derived galectin-3 in neuroinflammation; a bittersweet ligand?

Rahimian R, Béland LC, Sato S, Kriz J.

Med Res Rev. 2021 Jul;41(4):2582-2589. doi: 10.1002/med.21784. Epub 2021 Mar 18.

Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer's Disease

Kim J.

Int J Mol Sci. 2021 Mar 13;22(6):2929. doi: 10.3390/ijms22062929.

When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer's and Huntington's Disease

D'Mello SR.

Int J Mol Sci. 2021 May 31;22(11):5911. doi: 10.3390/ijms22115911.

Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases

Trudler D, Ghatak S, Lipton SA.

Int J Mol Sci. 2021 Jul 30;22(15):8196. doi: 10.3390/ijms22158196.

Hypoxia and the Kynurenine Pathway: Implications and Therapeutic Prospects in Alzheimer's Disease

Adeyemi OS, Awakan OJ, Afolabi LB, Rotimi DE, Oluwayemi E, Otuechere CA, Ibraheem O, Elebiyo TC, Alejolowo O, Arowolo AT.

Oxid Med Cell Longev. 2021 Nov 10;2021:5522981. doi: 10.1155/2021/5522981. eCollection 2021.

Insight γ-Secretase: Structure, Function, and Role in Alzheimer's Disease

Mal S, Malik U, Pal D, Mishra A.

Curr Drug Targets. 2021;22(12):1376-1403. doi: 10.2174/1389450121999201230203709.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias